conditions to a full-length reverse complement of a nucleic acid of SEQ ID NOS: 3, 5, 7 and 9 in a host and isolating said VEGF-B, wherein said high stringency conditions comprise 0.1-1X SSC/0.1% w/v SDS at 60°C for 1-3 hours.

51.(Twice Amended) A process for the production of biologically active VEGF-B, said method comprising expressing a nucleic acid molecule which hybridizes under high stringency conditions to a full-length reverse complement of a nucleic acid of SEQ ID NO:3 in a host and isolating said VEGF-B, wherein said high stringency conditions comprise 0.1-1X SSC/0.1% w/v SDS at 60°C for 1-3 hours.

52.(Twice Amended) A process for the production of biologically active VEGF-B, said method comprising expressing a nucleic acid molecule which hybridizes under high stringency conditions to a full-length reverse complement of a nucleic acid of SEQ ID NO:5 in a host and isolating said VEGF-B, wherein said high stringency conditions comprise 0.1-1X SSC/0.1% w/v SDS at 60°C for 1-3 hours.

53.(Twice Amended) A process for the production of biologically active VEGF-B, said method comprising expressing a nucleic acid molecule which hybridizes under high stringency conditions to a full-length reverse complement of a nucleic acid of SEQ ID NO:7 in a host and isolating said VEGF-B, wherein said high stringency conditions comprise 0.1-1X SSC/0.1% w/v SDS at 60°C for 1-3 hours.